TY - JOUR
T1 - Clinical outcome and olanzapine plasma levels in acute schizophrenia
AU - Mauri, M. C.
AU - Steinhilber, C. P C
AU - Marino, R.
AU - Invernizzi, E.
AU - Fiorentini, A.
AU - Cerveri, G.
AU - Baldi, M. L.
AU - Barale, F.
PY - 2005/1
Y1 - 2005/1
N2 - Purpose. - This open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients. Material and methods. - A total of 54 inpatients, 38 males and 16 females, age ranging from 18 to 75:years, affected by Schizophrenia (DSM IV criteria) during an exacerbation phase were included in the study. Olanzapine (OLZ) was started at a dose of 5-20:mg/day and was increased to a mean dose of 15.27:mg ±5.53 S.D. Patients were evaluated at baseline, and after 2:weeks, by using BPRS, PANNS, HRS-D, EPSE, and ACS. Results. - BPRS and total PANSS showed a statistically significant improvement at the end of the study. Olanzapine plasma levels (PL) ranged from 5 to 120:ng/ml (mean 33.15:ng/ml ± 28.28 S.D.) and showed a positive correlation with OLZ dosage. A significant curvilinear correlation between OLZ PL and clinical improvement (BPRS, PANSS and HRS-D percent of amelioration) was observed. Conclusion. - Olanzapine plasma level determination seems to be a useful tool in optimizing acute treatment particularly for more problematic cases.
AB - Purpose. - This open label study was performed to evaluate the relationship between the plasma concentration of olanzapine and the response in acute schizophrenic inpatients. Material and methods. - A total of 54 inpatients, 38 males and 16 females, age ranging from 18 to 75:years, affected by Schizophrenia (DSM IV criteria) during an exacerbation phase were included in the study. Olanzapine (OLZ) was started at a dose of 5-20:mg/day and was increased to a mean dose of 15.27:mg ±5.53 S.D. Patients were evaluated at baseline, and after 2:weeks, by using BPRS, PANNS, HRS-D, EPSE, and ACS. Results. - BPRS and total PANSS showed a statistically significant improvement at the end of the study. Olanzapine plasma levels (PL) ranged from 5 to 120:ng/ml (mean 33.15:ng/ml ± 28.28 S.D.) and showed a positive correlation with OLZ dosage. A significant curvilinear correlation between OLZ PL and clinical improvement (BPRS, PANSS and HRS-D percent of amelioration) was observed. Conclusion. - Olanzapine plasma level determination seems to be a useful tool in optimizing acute treatment particularly for more problematic cases.
KW - Acute schizophrenia
KW - Olanzapine
KW - Plasma levels
UR - http://www.scopus.com/inward/record.url?scp=11844257017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11844257017&partnerID=8YFLogxK
U2 - 10.1016/j.eurpsy.2004.09.009
DO - 10.1016/j.eurpsy.2004.09.009
M3 - Article
C2 - 15642445
AN - SCOPUS:11844257017
SN - 0924-9338
VL - 20
SP - 55
EP - 60
JO - Psychiatrie et Psychobiologie
JF - Psychiatrie et Psychobiologie
IS - 1
ER -